FDA Aims For Flexibility In Upcoming Drug/Test Co-Development Guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed